Clinical trials: APOL1-mediated Kidney Disease
Glomerulosclerosis, Focal Segmental
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT04340362
- Testing
- VX-147
- Where
- 44 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Vertex Pharmaceuticals Incorporated